Tom 11, Nr 1 (2019)
Artykuły
Opublikowany online: 2019-05-02

dostęp otwarty

Wyświetlenia strony 2207
Wyświetlenia/pobrania artykułu 155
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Ablacja guzów trzustki prądem o częstotliwości fal radiowych pod kontrolą ultrasonografii endoskopowej

Marcin Polkowski
Gastroenterologia Kliniczna 2019;11(1):33-38.

Streszczenie

W artykule omówiono wstępne wyniki leczenia litych i torbielowatych guzów trzustki za pomocą termicznej ablacji prądem o częstotliwości fal radiowych (RFA) wykonywanej pod kontrolą ultrasonografii endoskopowej (EUS). Prace laboratoryjne i na zwierzętach wykazują, że RFA pod kontrolą EUS skutecznie wytwarza ograniczoną przestrzenie martwicę tkanki trzustki i jest bezpieczne. Doświadczenie kliniczne jest ograniczone. Metoda była stosowana w leczeniu niewielkich grup chorych z nowotworami neuroendokrynnymi (NET), nowotworami torbielowatymi i nieresekcyjnym rakiem trzustki. Skuteczność leczenia oceniano na podstawie badań obrazowych ukierunkowanych na wykrycie martwicy guza, a u chorych z czynnymi hormonalnie NET, na kontroli objawów klinicznych. Najczęstszym działaniem niepożądanym były przejściowe bóle brzucha po zabiegu obserwowane u 0–38% leczonych. Opisano pojedyncze przypadki ostrego zaplenia trzustki o nieciężkim przebiegu, perforacji jelita cienkiego i zwężenia przewodu Wirunga wymagającego leczenia endoskopowego.

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Nimptsch U, Krautz C, Weber GF, et al. Nationwide In-hospital Mortality Following Pancreatic Surgery in Germany is Higher than Anticipated. Ann Surg. 2016; 264(6): 1082–1090.
  2. Krautz C, Nimptsch U, Weber GF, et al. Effect of Hospital Volume on In-hospital Morbidity and Mortality Following Pancreatic Surgery in Germany. Ann Surg. 2018; 267(3): 411–417.
  3. Scheiman JM, Hwang JHa, Moayyedi P. American gastroenterological association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015; 148(4): 824–48.e22.
  4. Nell S, Borel Rinkes IHM, Verkooijen HM, et al. DMSG. Early and Late Complications After Surgery for MEN1-related Nonfunctioning Pancreatic Neuroendocrine Tumors. Ann Surg. 2018; 267(2): 352–356.
  5. Sadot E, Reidy-Lagunes DL, Tang LH, et al. Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study. Ann Surg Oncol. 2016; 23(4): 1361–1370.
  6. Jung JGu, Lee KT, Woo YS, et al. Behavior of Small, Asymptomatic, Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PNETs). Medicine (Baltimore). 2015; 94(26): e983.
  7. Lee LC, Grant CS, Salomao DR, et al. Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. Surgery. 2012; 152(6): 965–974.
  8. Gaujoux S, Partelli S, Maire F, et al. Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab. 2013; 98(12): 4784–4789.
  9. Kishi Y, Shimada K, Nara S, et al. Basing treatment strategy for non-functional pancreatic neuroendocrine tumors on tumor size. Ann Surg Oncol. 2014; 21(9): 2882–2888.
  10. Crippa S, Partelli S, Zamboni G, et al. Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors. Surgery. 2014; 155(1): 145–153.
  11. Rosenberg AM, Friedmann P, Del Rivero J, et al. Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors. Surgery. 2016; 159(1): 302–309.
  12. Partelli S, Cirocchi R, Crippa S, et al. Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms. Br J Surg. 2017; 104(1): 34–41.
  13. Sharpe SM, In H, Winchester DJ, et al. Surgical resection provides an overall survival benefit for patients with small pancreatic neuroendocrine tumors. J Gastrointest Surg. 2015; 19(1): 117–23; discussion 123.
  14. Tanaka M, Fernández-del Castillo C, Adsay V, et al. International Association of Pancreatology. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012; 12(3): 183–197.
  15. American Gastroenterological Association. Management of asymptomatic neoplastic pancreatic cysts: clinical decision support tool. Gastroenterology. 2015; 148(4): 823.
  16. European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018; 67(5): 789–804.
  17. Dietrich CF, Sahai AV, D'Onofrio M, et al. Differential diagnosis of small solid pancreatic lesions. Gastrointest Endosc. 2016; 84(6): 933–940.
  18. Kuo EJ, Salem RR. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size. Ann Surg Oncol. 2013; 20(9): 2815–2821.
  19. Lakhtakia S. Therapy of pancreatic neuroendocrine tumors: fine needle intervention including ethanol and radiofrequency ablation. Clin Endosc. 2017; 50(6): 546–551.
  20. Sofi AA, Khan MA, Das A, et al. Radiofrequency ablation combined with biliary stent placement versus stent placement alone for malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc. 2018; 87(4): 944–951.e1.
  21. Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018; 67(1): 358–380.
  22. Xu XL, Liu XD, Liang M, et al. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: systematic review of randomized controlled trials with meta-analysis and trial sequential analysis. Radiology. 2018; 287(2): 461–472.
  23. Weinstein JL, Ahmed M. Percutaneous ablation for hepatocellular carcinoma. AJR Am J Roentgenol. 2018; 210(6): 1368–1375.
  24. Cirimbei C, Rotaru V, Chitoran E, et al. Immediate and long-term results of radiofrequency ablation for colorectal liver metastases. Anticancer Res. 2017; 37(11): 6489–6494.
  25. Park HS, Baek JH, Park AW, et al. Thyroid radiofrequency ablation: updates on innovative devices and techniques. Korean J Radiol. 2017; 18(4): 615–623.
  26. Zhou K, Pan J, Yang N, et al. Effectiveness and safety of CT-guided percutaneous radiofrequency ablation of adrenal metastases. Br J Radiol. 2018; 91(1085): 20170607.
  27. Fleming MM, Holbrook AI, Newell MS. Update on image-guided percutaneous ablation of breast cancer. AJR Am J Roentgenol. 2017; 208(2): 267–274.
  28. Yuan Z, Wang Y, Zhang J, et al. A meta-analysis of clinical outcomes after radiofrequency ablation and microwave ablation for lung cancer and pulmonary metastases. J Am Coll Radiol. 2019; 16(3): 302–314.
  29. Girelli R, Frigerio I, Giardino A, et al. Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. Langenbecks Arch Surg. 2013; 398(1): 63–69.
  30. Girelli R, Frigerio I, Salvia R, et al. Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Br J Surg. 2010; 97(2): 220–225.
  31. Spiliotis JD, Datsis AC, Michalopoulos NV, et al. Radiofrequency ablation combined with palliative surgery may prolong survival of patients with advanced cancer of the pancreas. Langenbecks Arch Surg. 2007; 392(1): 55–60.
  32. Wu Y, Tang Z, Fang H, et al. High operative risk of cool-tip radiofrequency ablation for unresectable pancreatic head cancer. J Surg Oncol. 2006; 94(5): 392–395.
  33. Matsui Y, Nakagawa A, Kamiyama Y, et al. Selective thermocoagulation of unresectable pancreatic cancers by using radiofrequency capacitive heating. Pancreas. 2000; 20(1): 14–20.
  34. Rombouts SJE, Derksen TC, Nio CY, et al. Computed tomography findings after radiofrequency ablation in locally advanced pancreatic cancer. Abdom Radiol (NY). 2018; 43(10): 2702–2711.
  35. D'Onofrio M, Crosara S, De Robertis R, et al. Percutaneous radiofrequency ablation of unresectable locally advanced pancreatic cancer: preliminary results. Technol Cancer Res Treat. 2017; 16(3): 285–294.
  36. Goldberg SN, Mallery S, Gazelle GS, et al. EUS-guided radiofrequency ablation in the pancreas: results in a porcine model. Gastrointest Endosc. 1999; 50(3): 392–401.
  37. Silviu UB, Daniel P, Claudiu M, et al. Endoscopic ultrasound-guided radiofrequency ablation of the pancreas: An experimental study with pathological correlation. Endosc Ultrasound. 2015; 4(4): 330–335.
  38. Carrara S, Arcidiacono PG, Albarello L, et al. Endoscopic ultrasound-guided application of a new hybrid cryotherm probe in porcine pancreas: a preliminary study. Endoscopy. 2008; 40(4): 321–326.
  39. Kim HJ, Seo DW, Hassanuddin A, et al. EUS-guided radiofrequency ablation of the porcine pancreas. Gastrointest Endosc. 2012; 76(5): 1039–1043.
  40. Barret M, Leblanc S, Rouquette A, et al. EUS-guided pancreatic radiofrequency ablation: preclinical comparison of two currently available devices in a pig model. Endosc Int Open. 2019; 7(2): E138–E143.
  41. Lakhtakia S, Ramchandani M, Galasso D, et al. EUS-guided radiofrequency ablation for management of pancreatic insulinoma by using a novel needle electrode (with videos). Gastrointest Endosc. 2016; 83(1): 234–239.
  42. Pai M, Habib N, Senturk H, et al. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. World J Gastrointest Surg. 2015; 7(4): 52–59.
  43. Barthet M, Giovannini M, Lesavre N, et al. Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors and pancreatic cystic neoplasms: a prospective multicenter study. Endoscopy. 2019 [Epub ahead of print].
  44. Choi JH, Seo DW, Song TJ, et al. Endoscopic ultrasound-guided radiofrequency ablation for management of benign solid pancreatic tumors. Endoscopy. 2018; 50(11): 1099–1104.
  45. Crinò SF, D'Onofrio M, Bernardoni L, et al. EUS-guided radiofrequency ablation (EUS-RFA) of solid pancreatic neoplasm using an 18-gauge needle electrode: feasibility, safety, and technical success. J Gastrointestin Liver Dis. 2018; 27(1): 67–72.
  46. Scopelliti F, Pea A, Conigliaro R, et al. Technique, safety, and feasibility of EUS-guided radiofrequency ablation in unresectable pancreatic cancer. Surg Endosc. 2018; 32(9): 4022–4028.
  47. Song TJ, Seo DW, Lakhtakia S, et al. Initial experience of EUS-guided radiofrequency ablation of unresectable pancreatic cancer. Gastrointest Endosc. 2016; 83(2): 440–443.
  48. Arcidiacono PG, Carrara S, Reni M, et al. Feasibility and safety of EUS-guided cryothermal ablation in patients with locally advanced pancreatic cancer. Gastrointest Endosc. 2012; 76(6): 1142–1151.